PharmaResources (Shanghai) Co. Ltd. A (SHE:301230) — Market Cap & Net Worth
Market Cap & Net Worth: PharmaResources (Shanghai) Co. Ltd. A (301230)
PharmaResources (Shanghai) Co. Ltd. A (SHE:301230) has a market capitalization of $845.63 Million (CN¥5.78 Billion) as of May 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #9881 globally and #2802 in its home market, demonstrating a -5.52% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PharmaResources (Shanghai) Co. Ltd. A's stock price CN¥41.40 by its total outstanding shares 139586605 (139.59 Million). Analyse PharmaResources (Shanghai) Co. Ltd. A (301230) cash flow conversion to see how efficiently the company converts income to cash.
PharmaResources (Shanghai) Co. Ltd. A Market Cap History: 2022 to 2026
PharmaResources (Shanghai) Co. Ltd. A's market capitalization history from 2022 to 2026. Data shows growth from $582.11 Million to $845.63 Million (12.61% CAGR).
PharmaResources (Shanghai) Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PharmaResources (Shanghai) Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.96x
PharmaResources (Shanghai) Co. Ltd. A's market cap is 0.96 times its annual revenue
Latest Price to Earnings (P/E) Ratio
30.51x
PharmaResources (Shanghai) Co. Ltd. A's market cap is 30.51 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $582.11 Million | $478.88 Million | $67.18 Million | 1.22x | 8.67x |
| 2023 | $552.61 Million | $489.72 Million | $37.62 Million | 1.13x | 14.69x |
| 2024 | $521.27 Million | $544.47 Million | $17.08 Million | 0.96x | 30.51x |
Competitor Companies of 301230 by Market Capitalization
Companies near PharmaResources (Shanghai) Co. Ltd. A in the global market cap rankings as of May 4, 2026.
Key companies related to PharmaResources (Shanghai) Co. Ltd. A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
PharmaResources (Shanghai) Co. Ltd. A Historical Marketcap From 2022 to 2026
Between 2022 and today, PharmaResources (Shanghai) Co. Ltd. A's market cap moved from $582.11 Million to $ 845.63 Million, with a yearly change of 12.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥845.63 Million | +38.60% |
| 2025 | CN¥610.12 Million | +17.05% |
| 2024 | CN¥521.27 Million | -5.67% |
| 2023 | CN¥552.61 Million | -5.07% |
| 2022 | CN¥582.11 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of PharmaResources (Shanghai) Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $845.63 Million USD |
| MoneyControl | $845.63 Million USD |
| MarketWatch | $845.63 Million USD |
| marketcap.company | $845.63 Million USD |
| Reuters | $845.63 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PharmaResources (Shanghai) Co. Ltd. A
PharmaResources (Shanghai) Co., Ltd. engages in new drug research, development, and commercial production in China. It offers small molecule drug CRO, CDMO, and CMO. The company also involved in drug discovery, research, and development of pharmaceutical processes; and customized and commercial production of APIs, and key intermediates. It serves global pharmaceutical and biotechnology companies.… Read more